Promising combo for tough leukemia falls short in early trial
NCT ID NCT05780879
First seen Mar 31, 2026 · Last updated May 25, 2026 · Updated 10 times
Summary
This study tested whether adding the drug venetoclax to standard chemotherapy could help people with a hard-to-treat type of leukemia called secondary acute myeloid leukemia (sAML). The trial aimed to enroll 20 newly diagnosed patients but was stopped early after only 10 joined. Researchers wanted to see if the combination could lead to complete remission, meaning no signs of cancer in the bone marrow. Because the study was terminated, results are limited and the approach needs more research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.